BcI-2 expression and response to chemotherapy in colorectal adenocarcinomas
1997

Bcl-2 Expression and Chemotherapy Response in Colorectal Cancer

Sample size: 231 publication Evidence: low

Author Information

Author(s): HJ Schneider, SA Sampson, D Cunningham, AR Norman, HJN Andreyev, JVT Tilsed, PA Clarke

Primary Institution: Royal Marsden Hospital and Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research

Hypothesis

Does bcl-2 expression influence response to chemotherapy in colorectal adenocarcinomas?

Conclusion

Bcl-2 expression does not significantly influence response to chemotherapy or survival in patients with colorectal adenocarcinoma.

Supporting Evidence

  • 149 out of 231 tumors (64.5%) overexpressed bcl-2.
  • Bcl-2 expression was associated with low plasma CEA levels (P=0.013).
  • Bcl-2 expression did not influence overall survival or response to chemotherapy.

Takeaway

This study looked at whether a protein called bcl-2 affects how well chemotherapy works for colorectal cancer, and it found that it doesn't really make a difference.

Methodology

The study analyzed bcl-2 expression in 231 colorectal tumors from patients treated with surgery alone or with chemotherapy.

Limitations

The study did not find a significant association between bcl-2 expression and survival or response to chemotherapy.

Statistical Information

P-Value

P=0.013 for plasma CEA levels; P=0.049 for differentiation

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication